598 related articles for article (PubMed ID: 11228533)
1. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
2. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells.
Grangeon C; Cormary C; Douin-Echinard V; Favre G; Couderc B; Tilkin-Mariamé AF
Cancer Gene Ther; 2002 Mar; 9(3):282-8. PubMed ID: 11896445
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.
Couderc B; Zitvogel L; Douin-Echinard V; Djennane L; Tahara H; Favre G; Lotze MT; Robbins PD
Cancer Gene Ther; 1998; 5(3):163-75. PubMed ID: 9622100
[TBL] [Abstract][Full Text] [Related]
4. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules.
Cormary C; Gonzalez R; Faye JC; Favre G; Tilkin-Mariamé AF
Cancer Gene Ther; 2004 Jul; 11(7):497-507. PubMed ID: 15153937
[TBL] [Abstract][Full Text] [Related]
5. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
6. Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence.
Yoshimura K; Hazama S; Iizuka N; Yoshino S; Yamamoto K; Muraguchi M; Ohmoto Y; Noma T; Oka M
Cancer Gene Ther; 2001 Jan; 8(1):9-16. PubMed ID: 11219497
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
[TBL] [Abstract][Full Text] [Related]
8. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
9. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity.
Cormary C; Hiver E; Mariamé B; Favre G; Tilkin-Mariamé AF
Cancer Gene Ther; 2005 Dec; 12(12):963-72. PubMed ID: 15956983
[TBL] [Abstract][Full Text] [Related]
10. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
[TBL] [Abstract][Full Text] [Related]
11. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
[TBL] [Abstract][Full Text] [Related]
13. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model.
Emtage PC; Wan Y; Bramson JL; Graham FL; Gauldie J
J Immunol; 1998 Mar; 160(5):2531-8. PubMed ID: 9498799
[TBL] [Abstract][Full Text] [Related]
14. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
[TBL] [Abstract][Full Text] [Related]
15. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
16. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
Zibert A; Thomassen A; Müller L; Nguyen L; Glouchkova L; Fraefel C; Roskrow M; Meisel R; Dilloo D
Gene Ther; 2005 Dec; 12(23):1707-17. PubMed ID: 16034459
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases.
Nanni P; Rossi I; De Giovanni C; Landuzzi L; Nicoletti G; Stoppacciaro A; Parenza M; Colombo MP; Lollini PL
Cancer Res; 1998 Mar; 58(6):1225-30. PubMed ID: 9515809
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models.
Hiroishi K; Tüting T; Tahara H; Lotze MT
Gene Ther; 1999 Dec; 6(12):1988-94. PubMed ID: 10637450
[TBL] [Abstract][Full Text] [Related]
20. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G
Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]